ZOMDF — Zomedica Corp.

OTC · Health Care · Pharmaceuticals · CIK 1684144 ·
Last close
$0.10
Market Cap
$102.40M
52W High
$0.14
52W Low
$0.09
ADV30
946,012
Next earnings
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. It offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. The company provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, Assisi EquiLoop, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 8,799,000 5,484,000 -4,900,000 -4,534,000 121,533,000 9,369,000 10,588,000
Dec 2025 10,471,000 7,170,000 -5,164,000 -4,530,000 127,039,000 9,017,000 11,642,000
Jun 2025 6,964,000 4,666,000 -8,035,000 -7,398,000 136,472,000 8,129,000 11,115,000
Mar 2025 6,500,000 4,407,000 -8,715,000 -63,809,000 142,993,000 8,837,000 10,549,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-17,514,000
Investing CF
$17,450,000
Financing CF
$0
CapEx
$-2,879,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.09
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-299,773,000
Inventory
$5,545,000
Receivables
$3,455,000
ST Investments
$44,239,000
EBIT TTM
$-29,329,000
Pretax Income TTM
$-83,411,000
Interest Exp TTM
$0
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$34,329,000
EBITDA
$-17,077,000
Free Cash Flow
$-8,171,625
Enterprise Value
$56,810,744
Total Cash
$47,507,000
Total Debt
$2,011,000
Shares Out
979,949,668
Trailing EPS
$-0.01
Book Value
$0.12
ROE
-18.6%
ROA
-11.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 32,030,000 -28,520,000 -81,858,000 127,039,000 11,642,000 -17,649,000
Dec 2024 27,285,000 -35,029,000 -46,982,000 207,360,000 11,696,000 -23,630,000
Dec 2023 25,186,000 -31,592,000 -34,529,000 253,197,000 13,180,000 -15,975,000
Dec 2022 18,930,000 -21,923,000 -17,015,000 279,610,000 12,218,000 -11,670,000

Peers — same industry

TickerNameMarket CapLastDaily %
BMEA Biomea Fusion, Inc. $101.94M $1.41
PYXS Pyxis Oncology, Inc. $103.27M $1.63
RVRC Revium Rx. $101.42M $1.67
VRCA Verrica Pharmaceuticals Inc. $103.42M $6.02
INO INOVIO PHARMACEUTICALS, INC. $103.66M $1.26

News headlines (Yahoo Finance, 1h cache)

Zomedica's PulseVet System Repeats as Official Shock Wave of the United States Eventing Association
2026-05-20 10:00 · Yahoo
Zomedica Announces "Fifth Friday at Four" Webinar on May 29th: First Quarter 2026 Financial Results and a Deep Dive into the Companion Animal VetTech Market
2026-05-14 10:00 · Yahoo
Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
2026-05-06 21:05 · Yahoo
Zomedica Announces “Fourth Friday at Four” Webinar on April 24th: A Behind-the-Scenes Look at Manufacturing Excellence and Operational Scale
2026-04-16 21:32 · Yahoo
Zomedica Announces Strategic Collaboration with Boehringer Ingelheim to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform
2026-03-18 10:00 · Yahoo
Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million i
2026-03-16 20:30 · Yahoo
Zomedica to Review 2025 Financial Results and Highlight Equine Market Opportunity During March 27th "Fourth Friday at Four" Investor Webinar
2026-03-10 10:30 · Yahoo
Zomedica Expands Distribution of TRUVIEW(R) Digital Microscopy Platform Through National Agreement with Moichor, a Leader in Veterinary Pathology
2026-02-25 11:30 · Yahoo
Diality Appoints Peter Donato as Chief Financial Officer
2026-02-24 12:05 · Yahoo
Zomedica Announces "Fourth Friday at Four" Webinar on February 27th Focused on Research & Development and Its Innovation Pipeline
2026-02-05 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.